parallel randomized trial

S003064

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Other conditionsS003064

Design

Randomized: 42
Start year: 2015
Treatment: 13.04 weeks, follow-up 13.04 weeks
Countries: China (1 sites)
Sponsor: (not reported)
Eligibility: children aged 6 to 18 with prediabetes

Conduct and analysis

Blinding: not reported
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Standard care or no added treatment Lifestyle intervention (control)	diet and exercise prescription with telephone and outpatient follow up; lifestyle: standard	21
A2	Liraglutide 1.2 mg subcutaneous once daily Liraglutide 1.2 mg plus lifestyle	diet and exercise prescription with telephone and outpatient follow up; lifestyle: standard	21

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Standard care or no added treatment A1	Liraglutide 1.2 mg subcutaneous once daily A2
age	mean (years)	11.12	11.19
age	sd (years)	2.10	2.27
bmi	mean (kg/m2)	30.89	30.98
bmi	sd (kg/m2)	5.02	4.97
female	n	6	7
hba1c	mean (percent)	5.85	5.87
hba1c	sd (percent)	1.33	1.35